Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis
Zeitschrift für Rheumatologie, 03/04/2011
Willeke P et al. – Contrary to the assumption of rheumatologists, the authors have demonstrated a preference among Rituximab (RTX) patients for i.v. drug administration every 6–9 months over other methods of administration.



